Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics - Open
Published in: PharmacoEconomics - Open 2/2017

Open Access 01-06-2017 | Original Research Article

Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015

Authors: Ziyad S. Almalki, Xiaomeng Yue, Ying Xia, Patricia R. Wigle, Jeff Jianfei Guo

Published in: PharmacoEconomics - Open | Issue 2/2017

Login to get access

Abstract

Background

Given that the quinolones is one of the antibacterial classes most frequently used to treat patients with bacterial infections in the United States, any change in prescribing patterns of quinolones will impact Medicaid medical expenditures.

Objectives

This study was undertaken to examine trends in utilization, reimbursement, and prices of quinolone antibacterials for the US Medicaid population.

Methods

The publicly available Medicaid State Drug Utilization outpatient pharmacy files were used for this study. Quarterly and annual prescription counts and reimbursement amounts were calculated for each of the quinolones reimbursed by Medicaid from quarter 1, 1991 through quarter 2, 2015. Average per-prescription reimbursement, as a proxy for drug price, was calculated as the drug reimbursement divided by the number of prescriptions.

Results

The total annual number of quinolone prescriptions increased 402%, from 247,395 in the first quarter of 1991 to 1.2 million in the second quarter of 2015, peaking at 1.3 million in the first quarter of 2005. Similarly, the total reimbursement for quinolone agents increased by 245.5% over the same period. More than 80% of quinolone prescriptions reimbursed by Medicaid were for the second-generation agent, ciprofloxacin, and the third-generation agent, levofloxacin. The average payment per prescription for quinolones increased from US$43.8 in the first quarter of 1991 to US$87.6 in the second quarter of 2015.

Conclusions

A substantial rise in Medicaid expenditures on quinolones was observed during the 25-year study period, which was mainly because of rising utilization. Therefore, there is a need for additional research that has access to clinically relevant data with which to measure the rate of inappropriate quinolone use among the Medicaid population and associated clinical outcomes and healthcare costs.
Appendix
Available only for authorised users
Literature
1.
Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff. 2001;20(5):241–51.CrossRef
2.
Nett RJ, et al. Office-related antibiotic prescribing for Medicaid-enrolled children. Clin Pediatr: 0009922813479158 (2013).
3.
Berman S, et al. Otitis media-related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric Medicaid population. Pediatrics.1997;100.4: 585–592.
4.
Linder JA, et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118(3):259–68.CrossRefPubMed
5.
Lesher GY, et al. 1, 8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Chem. 1962;5(5):1063–5.CrossRef
6.
Suda KJ, et al. A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009. J Antimicrob Chemother. 2012: dks445.
7.
Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs. 1999;58(Suppl 2):29–36.CrossRefPubMed
8.
Hane MW, Wood TH. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J Bacteriol. 1969;99:238–41.PubMedPubMedCentral
9.
Yoshida H, Kojima T, Yamagishi J, Nakamura S. Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet. 1988;211:1–7.CrossRefPubMed
10.
Nakamura S, Nakamura M, Kojima T, Yoshida H. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob Agents Chemother. 1989;33:254–5.CrossRefPubMedPubMedCentral
11.
Phillips I, King A, Shannon K. Comparative in vitro properties of the quinolones. In: Andriole VT, editor. the quinolones. 3rd ed. San Diego: Academic Press; 2000. p. 99–137.CrossRef
12.
13.
Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis. 1987;9(6):1065–78.CrossRefPubMed
14.
Linden PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med. 1998;104(5):24S–33S.CrossRefPubMed
15.
Goff DA. Antimicrobial stewardship: bridging the gap between quality care and cost. Curr Opin Infect Dis. 2011;24:S11–20.CrossRefPubMed
16.
17.
Lee GC, et al. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med. 2014;12(1):1.CrossRef
18.
Patrick SW, Freed GL. Intergenerational enrollment and expenditure changes in Medicaid: trends from 1991 to 2005. BMC Health Serv Res. 2012;12(1):1.CrossRef
19.
20.
21.
22.
23.
24.
Jing Y, et al. Utilization and spending trends for antiretroviral medications in the US Medicaid program from 1991 to 2005. AIDS Res Therapy. 2007;4(1):1.CrossRef
25.
Chen Y, et al. Utilization, price, and spending trends for antidepressants in the US Medicaid Program. Res Soc Adm Pharm. 2008;4(3):244–57.CrossRef
26.
Bian B, et al. ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. J Manage Care Pharm. 2010;16(9):671–9.
27.
Chiu S-F, et al. Utilization, spending, and price trends for short-and long-acting Beta-agonists and inhaled corticosteroids in the medicaid program, 1991–2010. Am Health Drug Benefits.2011; 4.3.
28.
Desai VC, et al. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991–2009. Clin Ther. 2012;34(10):2118–31.CrossRefPubMed
29.
Gorevski E, et al. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991–2009. Ann Pharmacother. 2012;46(4):503–12.CrossRefPubMed
30.
Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? Am J Health-Syst Pharm. 1997;54(22):2569–84.PubMed
31.
32.
33.
Bruen BK, Miller LM. Changes in Medicaid prescription volume and use in the wake of Medicare Part D implementation. Health Aff. 2008;27(1):196–202.CrossRef
34.
35.
Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl. 2):S144–57.CrossRefPubMed
36.
Dydek GJ, Souney PF, Matthews SJ. DUE of ciprofloxacin in the treatment of urinary tract infections in hospitalized patients. Hosp Formul. 1992;27(2):185–91.PubMed
37.
Lautenbach E, et al. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med. 2003;163(5):601–5.CrossRefPubMed
38.
Almalki ZS, Alahmari AK, Guo JJ, Cavanaugh TM. Off-label use of oral fluoroquinolone antibiotics in outpatient settings in the United States, 2006 to 2012. Pharmacoepidemiol Drug Saf. 2016;25:1042–251.CrossRefPubMed
39.
40.
Belongia EA, Sullivan BJ, Chyou PH, Madagame E, Reed KD, Schwartz B. A community intervention trial to promote judicious antibiotic use and reduce penicillin-resistant Streptococcus pneumoniae carriage in children. Pediatrics. 2001;108:575–83.CrossRefPubMed
41.
Perz JF, Craig AS, Coffey CS, et al. Changes in antibiotic prescribing for children after a community-wide campaign. JAMA. 2002;287:3103–9.CrossRefPubMed
42.
Hennessy TW, Petersen KM, Bruden D, et al. Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: a controlled intervention trial in rural Alaska. Clin Infect Dis. 2002;34:1543–50.CrossRefPubMed
43.
Gonzales R, Corbett KK, Wong S, et al. “Get smart Colorado”: impact of a mass media campaign to improve community antibiotic use. Med Care. 2008;46:597–605.CrossRefPubMed
44.
Finkelstein JA, Huang SS, Kleinman K, et al. Impact of a16-community trial to promote judicious antibiotic use in Massachusetts. Pediatrics. 2008;121:e15–23.CrossRefPubMed
45.
Bauchner H, Pelton SI, Klein JO. Parents, physicians, and antibiotic use. Pediatrics. 1999;103(2):395–401.CrossRefPubMed
46.
47.
Werner NL, et al. Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis. 2011;11(1):1.CrossRef
48.
Carmeli Y, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43(6):1379–82.PubMedPubMedCentral
49.
Dziekan G, et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J Hosp Infect. 2000;46(4):263–70.CrossRefPubMed
50.
El Amari EB, et al. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis. 2001;33(11):1859–64.CrossRefPubMed
51.
Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother. 2002;49(6):999–1005.CrossRefPubMed
52.
Weber SG, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis. 2003;9(11):1415–22.CrossRefPubMedPubMedCentral
53.
Crowcroft NS, et al. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol. 1999;20(01):31–6.CrossRefPubMed
54.
Bhavnani SM, et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in US hospitals. Am J Health-Syst Pharm. 2003;60(19):1962–70.PubMed
55.
Zervos MJ, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000. Clin Infect Dis. 2003;37.12:1643–1648.
56.
Duggan M, Scott Morton F. The distortionary effects of government procurement: evidence from Medicaid prescription drug purchasing. No. w10930. National Bureau of Economic Research, 2004.
57.
Kelton CML, et al. Firm-and drug-specific patterns of generic drug payments by US Medicaid programs: 1991–2008. Appl Health Econ Health Policy. 2014;12(2):165–77.CrossRefPubMed
58.
Metadata
Title
Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015
Authors
Ziyad S. Almalki
Xiaomeng Yue
Ying Xia
Patricia R. Wigle
Jeff Jianfei Guo
Publication date
01-06-2017
Publisher
Springer International Publishing
Published in
PharmacoEconomics - Open / Issue 2/2017
Print ISSN: 2509-4262
Electronic ISSN: 2509-4254
DOI
https://doi.org/10.1007/s41669-016-0007-y

Other articles of this Issue 2/2017

PharmacoEconomics - Open 2/2017 Go to the issue

Original Research Article

Cost-Benefit Analysis of Telemedicine Systems/Units in Greek Remote Areas

Original Research Article

A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens

Original Research Article

Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process

Editorial

Model Registration: A Call to Action

Original Research Article

Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes

Erratum

Erratum to: Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations